Skip to main content
NewslettersWatchlist

Abbvie Inc(ABBV-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low200.85
Day High206.15
Open:205.79
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Baystreet
Invest in the Top S&P Stocks With This New ETF
Motley Fool
5 Dividend Stocks to Double Up on Right Now -- Plus Some Dividend ETFs
Motley Fool
AbbVie (ABBV) Q3 2024 Earnings Call Transcript
Motley Fool
3 Dividend Growth Stocks to Buy and Never Sell
Barchart
Nasdaq Futures Climb on Upbeat Alphabet Results, U.S. GDP Data and More Big Tech Earnings on Tap
Newswire.ca
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Ontario
Motley Fool
3 Dividend Growth Stocks You Can Buy and Hold Forever
Motley Fool
3 High-Yielding Dividend Stocks That Can Be Ideal Buys for Retirees
Barchart
Up 174% in 2024, Is It Too Late to Buy This Breakout Biotech Stock?
Motley Fool
Beat the Nasdaq With This Cash-Gushing Dividend Stock
Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
Newswire.ca
Nine Provinces Approve Accelerated Public Reimbursement of Diffuse Large B-Cell Lymphoma Treatment Under New Early Access Process
Barchart
3 Undervalued Dividend Aristocrats Poised for Explosive Gains in 2025
Motley Fool
3 Growth Stocks That Could Be Bargain Buys Right Now
Motley Fool
2 Magnificent Dividend Stocks to Buy and Hold Forever
MarketBeat
Best Pharma Stocks for Long-Term Investors: Growth and Dividends
Motley Fool
Prediction: These 2 High-Yield Dividend Stocks Will Outperform the S&P 500 Index in the Coming Decade
Motley Fool
There Are Only 28 S&P 500 Companies Warren Buffett Can't Buy Outright. Here's the Best of the Bunch for Income Investors.
Barchart
3 Highest-yielding Dividend Kings for Maximum Income and Stability
MarketBeat
AbbVie Stock Eyes New Highs: Analysts See Strong Growth Potential
Motley Fool
3 Magnificent Dividend Stocks to Buy in October
Motley Fool
Billionaires Are Loading Up on This High-Yield Dividend Stock. Should You?

Profile

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.